Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Gets Thumbs Up For Kids, But Cmte. Wants Follow-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Arthritis Advisory Committee urges Pfizer to create an active surveillance program to track potential safety issues from the use of the COX-2 inhibitor for juvenile rheumatoid arthritis.

You may also be interested in...



Celebrex-mas: Pfizer Gets Early Present With Juvenile RA Approval

Firm will have to conduct a long-term registry to further evaluate safety concerns with the COX-2 inhibitor, including cardiovascular events.

Celebrex-mas: Pfizer Gets Early Present With Juvenile RA Approval

Firm will have to conduct a long-term registry to further evaluate safety concerns with the COX-2 inhibitor, including cardiovascular events.

Celebrex JRA Indication To Be Evaluated By FDA Advisory Committee

Lack of long-term safety data “poses a special challenge” in weighing risks and benefits, FDA says in briefing documents.

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel